The National Institutes of Health’s Rapid Acceleration of Diagnostics initiative Friday awarded $248.7 million in contracts to produce four new laboratory tests and three new point-of-care tests to detect SARS-CoV-2.

The recipients have received or applied for emergency use authorizations from the Food and Drug Administration for the tests, which use new technologies such as next generation sequencing, CRISPR and integrated microfluidic chips that could increase testing capacity and speed results. 

“RADx moved incredibly quickly to select promising technologies through its ‘shark tank’ approach, investing in technologies that could boost America’s best-in-the-world COVID-19 testing capacity by millions more tests per day,” said Health and Human Services Secretary Alex Azar. “These technologies will help deliver faster results from labs and more and more test results within minutes at the point of care, which is especially important for settings like schools and nursing homes.”

Related News Articles

Headline
The AHA today urged the Department of Health and Human Services to reinstate the COVID-19 Provider Relief Fund reporting requirements outlined in its June 19…
Perspective
More than 200,000 of our friends, family members, fellow citizens and front-line workers have succumbed to COVID-19 since March. To put that in context, that’s…
Headline
The Food and Drug Administration today authorized for emergency use the first serology test to help identify individuals with antibodies to SARS-CoV-2 at the…
Headline
Two clinical trials launched in April to evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19 are expanding, the National…
Headline
The Centers for Medicare & Medicaid Services today announced $165 million in supplemental funding to help 33 states participating in the Money Follows…
Headline
The Centers for Disease Control and Prevention today awarded $200 million in Coronavirus Aid, Relief, and Economic Security Act funds to help states,…